Lymphoproliferation and gamma interferon (IFN--y) The interaction between specifically sensitized T cells and activated macrophage-effector cells is considered to be the hallmark of protective immunity against the pathogenic mycobacteria Mycobacterium tuberculosis and M. leprae (4). These cell populations communicate by means of a complex network of monokines and lymphokines, which is not yet completely understood (41). Mycobacterial infection primarily activates interleukin-2 (IL-2)-, gamma interferon (IFN--y)-, and lymphotoxin-secreting helper T cells belonging to the TH1 subset, at least under conditions of relative resistance such as tuberculoid leprosy (22, 55) . On the other hand, cytokine mRNA profiles in skin lesions from lepromatous leprosy patients (with a susceptible form of the disease) are suggestive of activation of helper T cells from the TH2 subset, producing IL-4, IL-5, and IL-10 (57). Similarly, mRNA coding for TH1 cytokines can be demonstrated in human skin from a tuberculin-induced delayed-type hypersensitivity reaction (53) and mice infected intravenously with live M. bovis BCG also demonstrate a preponderant TH1 cytokine secretion profile, although some susceptible strains such as BALB/c activate IL-4-producing TH2 cells to a certain extent in response to the infection (27).
subjects tested in this study. These results could be of value in the development of a subunit vaccine for tuberculosis and leprosy.
The interaction between specifically sensitized T cells and activated macrophage-effector cells is considered to be the hallmark of protective immunity against the pathogenic mycobacteria Mycobacterium tuberculosis and M. leprae (4) . These cell populations communicate by means of a complex network of monokines and lymphokines, which is not yet completely understood (41) . Mycobacterial infection primarily activates interleukin-2 (IL-2)-, gamma interferon (IFN--y)-, and lymphotoxin-secreting helper T cells belonging to the TH1 subset, at least under conditions of relative resistance such as tuberculoid leprosy (22, 55) . On the other hand, cytokine mRNA profiles in skin lesions from lepromatous leprosy patients (with a susceptible form of the disease) are suggestive of activation of helper T cells from the TH2 subset, producing IL-4, IL-5, and IL-10 (57) . Similarly, mRNA coding for TH1 cytokines can be demonstrated in human skin from a tuberculin-induced delayed-type hypersensitivity reaction (53) and mice infected intravenously with live M. bovis BCG also demonstrate a preponderant TH1 cytokine secretion profile, although some susceptible strains such as BALB/c activate IL-4-producing TH2 cells to a certain extent in response to the infection (27) . IFN--y has powerful immunomodulatory and macrophageactivating properties (38) and plays an essential role in protective immunity against these intracellular pathogens, as convincingly demonstrated in recent experiments with IFN--y and IFN--y receptor gene-disrupted mice (9, 10, 21, 26) . Also, a follow-up study on household contacts of multibacillary leprosy patients has reported a clear association between low IFN--y production in response to M. leprae and development of the disease (49) .
The specific antigens eliciting protective T-cell responses are not yet known for tuberculosis or leprosy, although a considerable number of proteins have now been identified by classical purification methods and particularly by recombinant DNA technology (58) . Live organisms have been reported for decades to be more effective in the generation of specific acquired resistance than are killed mycobacterial preparations (3) , and it has therefore been argued that secreted antigens, present in large amounts in early mycobacterial culture filtrates and produced only by actively metabolizing bacteria, could be essential for the induction of protective immunity (40) .
One of the major secreted antigens from M. tuberculosis and M. bovis BCG culture filtrate is a 30-32-kDa doublet protein, called Ag85 according to the Closs reference system for BCG antigens (6) . Ag85 is a widely cross-reactive antigen found in all mycobacterial species tested so far (56) (1) . Ag85 is actually a protein family with three members, 85A, 85B, and 85C, which can be separated by isoelectric focusing (16) and which are encoded by three distinct but related genes (7) . Ag85 is also present in M. leprae (42) , and the corresponding genes have been cloned and demonstrate about 90% homology at the protein level with those of M. bovis BCG or M tuberculosis (which are virtually identical) (12) (13) (14) . Cross-reactive (or identical) B-cell epitopes of Ag85 exist in M. eprae, M tuberculosis, and M bovis BCG, because monoclonal antibodies against Ag85 from BCG can be used for immunohistochemical analysis of the M. leprae cell wall surface (44) . Cross-reactive epitopes are also presented on the surface of M. leprae-infected macrophages in cutaneous infiltrates from leprosy lesions (45) .
We have previously reported that Ag85A purified from BCG culture filtrate is a strong T-cell antigen in peripheral blood mononuclear cell (PBMC) cultures from all healthy tuberculin-positive human volunteers and from some tuberculosis patients (29) . Furthermore, T cells from all lepromin-positive healthy subjects and paucibacillary leprosy patients also react with Ag85 from BCG, whereas T cells from multibacillary leprosy patients do not (33) . Reactive T cells against Ag85 are generated very early during M leprae infection, even before actual development of a positive skin test to lepromin can be detected (34) .
Ag85 not only is a very effective stimulus of lymphoproliferation but also triggers substantial IFN-,y production in human PBMC cultures. In a comparative study on T-cell stimulation with Ag85 and three mycobacterial stress proteins, i.e., the 18-kDa, 65-kDa (GroEL-related), and 70-kDa (DnaKrelated) proteins, Ag85 ranked clearly as the most potent IFN--y inducer in PBMC cultures from healthy leprominpositive subjects (35) . Finally, we have reported that Ag85 acts as a potent TH1 stimulus in mice infected intravenously with M bovis BCG, leading to substantial IL-2 and IFN--y production in spleen cell cultures, particularly from mice with the H-2b haplotype (27) . Recently, we have described the THlcell-epitope mapping of Ag85A in seven different BCG-infected mouse strains and have found that each H-2 haplotype reacts against a particular set of IL-2-and IFN-y-inducing Ag85A peptides (28) .
In this paper we describe the T-cell-epitope mapping of Ag85A in healthy tuberculin-and lepromin-positive volunteers and in patients with tuberculosis and leprosy, measuring lymphoproliferation and IFN--y secretion of PBMC stimulated in vitro with 28 overlapping 20-mer residues covering the complete mature 295-amino-acid sequence of antigen 85A from M tuberculosis.
MATERIALS AND METHODS
Subjects. Eleven patients with active pulmonary tuberculosis, who had been receiving multidrug therapy for at least 2 months, were monitored at the Sanatorium in Alsemberg. One of these patients (M) was human immunodeficiency virus positive and presented with pleural effusion and pulmonary tuberculosis; the other 10 patients were human immunodeficiency virus negative. Ten (12) (13) (14) .
were also included. Two of these (H and I) had just finished a full treatment course of six weekly instillations with immuno-BCG prior to blood sampling, and one (J) was strongly tuberculin positive when tested prior to immunotherapy. Seventeen leprosy patients diagnosed according to the RidleyJopling criteria (47) were studied before treatment. All were monitored in the Institut de Leprologie Appliquee de Dakar. Three were TT (polar tuberculoid), six were BT (borderline tuberculoid), seven were BL (borderline lepromatous), and one was LL (polar lepromatous). Eight healthy leprominpositive controls also entered the study. All leprosy patients and lepromin-positive subjects had been vaccinated with BCG in childhood. None of them presented clinical signs of tuberculosis at the time of blood sampling, nor was there any history of tuberculosis in their antecedents.
Antigen. Ag85 (30-32-kDa doublet) was purified from culture filtrate of M. bovis BCG by sequential chromatography on phenyl-Sepharose and DEAE-Sephacel (Pharmacia, Uppsala, Sweden) as previously described (11) and used at concentrations of 10 ,ug/ml.
Peptide synthesis. All peptides were synthesized on TentaGel S-RAM resin (Rapp Polymere, Tubingen, Germany), which is furnished with a linker designed to generate carboxyterminal amides upon cleavage. Fmoc-oL-amino group and t-butyl-based side chain protection was used (20) . The guanidino group of arginine was protected with the 2,2,5,7,8-pentamethylchroman-6-sulfonyl moiety, trityl protection was used for both histidine and cysteine, and t-butyloxycarbonyl protection was used for tryptophan. Most amino acids were coupled as O-pentafluorophenyl esters. Peptides were synthesized by using continuous-flow procedures on a model 9050 PepSynthesizer (Millipore Corp., Bedford, Mass.). Following synthesis, peptides were cleaved from the resin and side chain protection was removed by using 90% trifluoroacetic acid in the presence of the appropriate scavengers. Peptides were precipitated with t-butyl-methylether and extracted. They were further purified by reversed-phase high-pressure liquid chromatography and subsequently dissolved in RPMI 1640 medium (Gibco, Rockville, Mich.). Peptides covering the complete mature sequence of Ag85A from M. tuberculosis (MTAg85A) were synthesized as 20-mer molecules overlapping by 10 amino acids with the neighboring peptides, except for the carboxyterminal peptide, which was a 22-mer covering positions 274 to 295. The exact peptide sequences and the predicted T-cell HLA haplotyping. Serological class I (A, B, and C) and II (HLA-DR and HLA-DQ) phenotyping was performed by using the standard fluorochromasia microlymphocytotoxicity procedure on peripheral blood lymphocytes with antisera defined according to the World Health Organization nomenclature for factors of the human leukocyte antigen (HLA) system (HLA haplotypes are shown in Table 1 ).
RESULTS

Proliferative response and IFN-'y production in response to
Ag85A peptides in tuberculin-positive subjects without clinical symptoms of tuberculosis. PBMC from 10 of 10 tuberculinpositive subjects reacted with positive lymphoproliferation and IFN--y secretion in response to Ag85 and a number of MTAg85A synthetic peptides. Despite differences in HLA class I and II alleles, a limited number of peptides were recognized by PBMC from the majority of the individuals, indicating the promiscuous character of the reactivity (Fig. 2A,  upper squares) . Thus, peptides 6 and 15 induced a positive lymphoproliferative response in 8 of 10 and 9 of 10 subjects, respectively. Peptides 13 and 20 were recognized by PBMC from 5 of 10 and 4 of 10 subjects, respectively. Furthermore, other peptides located throughout the protein were recognized by PBMC from some individuals. The percentage of reactivity toward each peptide is summarized in Table 2 . IFN--y production paralleled the proliferative response for peptide 6 and to a lesser extent for peptide 15. Interestingly, the carboxy- terminal peptide 27 induced IFN--y in 4 of 10 individuals, whereas it stimulated proliferation in only 1 of 10 ( Fig. 2A, lower squares). IFN--y secretion was also measured in response to peptides 2 to 4 (4 of 10 subjects). PBMC nal peptides (peptides 2 to 4, four of five were reactive; peptides 6 to 8, four of five were reactive).
Proliferative response and IFN--y production in response to MTAg85A peptides in healthy lepromin-positive controls. Eight healthy lepromin-positive controls were studied. They were all positive in proliferation and in IFN-y secretion in response to Ag85 (Fig. 3A) . Screening of PBMC from these subjects with MT85A peptides showed a promiscuous recognition, with peptides 2, 5, and 25 and 26 inducing proliferation in 50 to 75% of the individuals (Table 2) . Individual peptides 2 and 10 and the overlapping peptides 26 and 27 induced significant IFN--y production in PBMC from five of eight (62.5%), five of eight (62.5%), and seven of eight (87.5%) healthy subjects, respectively.
Proliferative response and IFN-y production in response to Ag85 and MT85A peptides in paucibacillary and multibacillary leprosy patients. PBMC from all paucibacillary patients proliferated and produced IFN-,y in response to Ag85 (Fig.  3B) . Peptides from MT85A were also recognized, and, again, some were identical to those recognized by PBMC from healthy infected subjects (peptide 5 response in five of nine patients) and some showed a shift to the neighboring peptide (peptide 1 response in six of nine). Individual peptides 6, 8, 10, 21, 25, 26 , and 27 also induced proliferation in a limited number of paucibacillary patients (one or two patients). All paucibacillary patients giving a positive IFN--y production in response to Ag85 also gave an IFN--y response to peptide 1 (Fig. 3C) . Screening of PBMC showed that MT85A peptides 1, 5, and 16 induced T-cell proliferation in a very limited number of these multibacillary patients (one of eight [12. 5%], two of eight [25%], and one of eight [12. 5%], respectively). Some IFN--y secretion was detected in response to MT85A peptides in patients 18, 22, and 25. DISCUSSION Using a series of 20-mer synthetic overlapping peptides, we have defined potent T-cell-stimulatory and IFN--y-inducing epitopes on the Ag85A component of the Ag85 complex, particularly in skin-test-positive subjects without clinical manifestations of tuberculosis or leprosy. All peptides that were found stimulatory in this study contained predicted T-cell epitopes according to the TSites program combining four predictive algorithms (amphipathicity, Rothbard and Taylor motifs, and I-Ad and I-Ed binding motifs) (19) . However, the presumed site in peptide 23 (predicted as the strongest T-cell epitope) elicited a response in only a few subjects.
Peptides were recognized in a promiscuous manner, irrespective of the HLA haplotype. Thus, peptides 6 and 15 were recognized by 80 and 90% of the tuberculin-positive controls, respectively, and peptide 26 was recognized by 75% of the lepromin-positive controls. Similar promiscuous T-cell-epitope recognition has also been reported for other antigens such as the 38-kDa phosphate-binding protein of M. tuberculosis (54), tetanus toxin (24, 46) , and malaria antigen (50) .
Patients appeared to react to different epitopes from those recognized by healthy subjects. Interestingly, however, these "disease-associated" peptides turned out to be adjacent to the peptides recognized by healthy subjects, and this was found both in tuberculosis (shift from peptide 6 to peptide 7) and in leprosy (shift from peptide 2 to peptide 1). As these adjacent peptides are overlapping by 10 amino acids, we cannot yet exclude the possibility that actually the same amino acid region is recognized. Perhaps the accumulation of M. leprae or M. tuberculosis bacilli in the antigen-presenting cells of patients may alter their processing capacity compared with healthy primary infected subjects (5). It is possible that in heavily loaded macrophages, some bacilli leak into the cytoplasm and then trigger the endogenous pathway of antigen presentation, which could lead to the generation of different (possibly smaller) peptides (37) . Fine analysis with smaller peptides is needed to elucidate this matter.
Despite a 90% homology between the 85A proteins from M. tuberculosis and M. leprae, the epitopes recognized by the two populations studied were generally distinct, suggesting a species specificity at the T-cell level. On the other hand, the two populations studied were from entirely different geographical locations, and although peptide recognition was found to be largely promiscuous, it is possible that differences in distribution of major histocompatibility complex alleles in Belgium and Senegal are responsible for some of the differences observed. On the other hand, comparison of predicted T-cell epitopes according to TSites of the 85A sequences from M. tuberculosis and from M. leprae indicates that small sequence differences may be reflected by important changes in predicted T sites. Thus, residue 62 (in peptide 6) involves a change from (15, 18, 30, 32, 39, 54) , possibly because these antigens seem to function as less potent IFN-y inducers (35 (36) . Also, Harding et al. have shown that the presence inside the macrophages of polysaccharides and of microbial products (which is particularly the case for multibacillary patients) can inhibit major histocompatibility complex-dependent presentation of immunogenic proteins by inhibiting intracellular steps in antigen processing (23) . Decreased IL-2 secretion and IL-2 receptor expression could also be related to the unresponsiveness observed in lepromatous leprosy and tuberculosis (52) , and active inhibition by suppressor macrophages (31) or by IL-4-producing TH2 or CD8+ cells (48) is yet another alternative. In our hands, does not seem to be involved directly in the low proliferative and IFN--y response observed, because only picogram levels of IL-4 could be measured in PBMC culture supernatants from these unresponsive patients (data not shown).
Finally, IL-10 is known to inhibit antigen presentation to THI cells (25) and might be responsible for the lack of reactivity toward Ag85, but this remains to be analyzed. Preliminary data obtained with BCG-infected mice suggest, however, that IL-10 is not involved as a suppressor factor for IFN--y secretion in response to culture filtrate antigens, because IL-10 activity can be detected simultaneously with high IFN-y levels in culture filtrate-stimulated spleen cell cultures (29a). This high IL-10 and IFN--y cytokine secretion type was also reported to occur in infection with two other intracellular bacteria, Brucella and Listeria spp. (17, 51) and was recently found in cloned T-cell lines from tuberculosis patients (2) .
In conclusion, the T-cell-epitope mapping performed here indicates that peptides from Ag85A of M tuberculosis and M bovis BCG are recognized by IFN-y-producing T cells in a highly promiscuous manner. The strong recognition of MT85A (=BCG85A) peptides in healthy M leprae-infected controls and in paucibacillary leprosy patients is in favor of crossprotective epitopes shared between M leprae and M bovis BCG and may be related to the significant protection that could be conferred by BCG vaccine against leprosy in Venezuela (8) and northern Malawi (43) . These data may have implications for the development of future subunit vaccines for leprosy and tuberculosis.
